Utne KK, et al. - This trial examined if treatment of acute deep vein thrombosis (DVT) with rivaroxaban would reduce the rate of a subsequent post-thrombotic syndrome (PTS) and would improve the health-related quality of life (HRQoL) as compared to conventional anticoagulation with low molecular weight heparin (LMWH)/warfarin in patients diagnosed between 2011 and 2014. Findings exhibited that rivaroxaban-treated patients had a lower rate of PTS compared to those treated with warfarin. Furthermore, HRQoL appeared to be notably better in the rivaroxaban-treated patients. Following adjustment, HRQoL measured by EQ-VAS and VEINES-QOL/Sym remained significantly better. However, yielded data required cautious interpretation.